Patents by Inventor Takakuni Matsuda
Takakuni Matsuda has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230390399Abstract: An object of the present invention is to provide a storage-stable injectable preparation comprising a composition comprising a poorly soluble drug as an active ingredient and a dispersion medium. Another object of the present invention is to provide a compact, lightweight prefilled syringe by filling a syringe with the injectable preparation. The present invention provides an injectable preparation comprising a composition comprising a poorly soluble drug, a dispersion medium, and a specific suspending agent, the composition having a viscosity of 40 pascal-seconds or more in at least one point in the shear rate range of 0.01 to 0.02 s?1 end having a viscosity of 0.2 pascal-seconds or less in at least one point in the shear rate range of 900 to 1.000 s?1, as measured.Type: ApplicationFiled: December 30, 2022Publication date: December 7, 2023Applicant: OTSUKA PHARMACEUTICAL CO., LTD.Inventors: Daiki KANEKO, Takakuni MATSUDA, Yusuke HOSHIKA
-
Patent number: 11638757Abstract: An object of the present invention is to provide a storage-stable injectable preparation comprising a composition comprising a poorly soluble drug as an active ingredient and a dispersion medium. Another object of the present invention is to provide a compact, lightweight prefilled syringe by filling a syringe with the injectable preparation. The present invention provides an injectable preparation comprising a composition comprising a poorly soluble drug, a dispersion medium, and a specific suspending agent, the composition having a viscosity of 40 pascal-seconds or more in at least one point in the shear rate range of 0.01 to 0.02 s?1 and having a viscosity of 0.2 pascal-seconds or less in at least one point in the shear rate range of 900 to 1,000 s?1, as measured.Type: GrantFiled: August 4, 2021Date of Patent: May 2, 2023Assignee: Otsuka Pharmaceutical Co., Ltd.Inventors: Daiki Kaneko, Takakuni Matsuda, Yusuke Hoshika
-
Publication number: 20220249523Abstract: A formulation stably comprising a tolvaptan prodrug is provided. Specifically, a freeze-dried composition comprising a compound represented by Formula (1): or a metal salt thereof and a disaccharide is provided.Type: ApplicationFiled: March 27, 2020Publication date: August 11, 2022Applicant: OTSUKA PHARMACEUTICAL CO., LTD.Inventors: Takakuni MATSUDA, Nobutomo SAKO
-
Publication number: 20220096638Abstract: An object of the present invention is to provide a storage-stable injectable preparation comprising a composition comprising a poorly soluble drug as an active ingredient and a dispersion medium. Another object of the present invention is to provide a compact, lightweight prefilled syringe by filling a syringe with the injectable preparation. The present invention provides an injectable preparation comprising a composition comprising a poorly soluble drug, a dispersion medium, and a specific suspending agent, the composition having a viscosity of 40 pascal-seconds or more in at least one point in the shear rate range of 0.01 to 0.02 s?1 and having a viscosity of 0.2 pascal-seconds or less in at least one point in the shear rate range of 900 to 1,000 s?1, as measured.Type: ApplicationFiled: August 4, 2021Publication date: March 31, 2022Applicant: OTSUKA PHARMACEUTICAL CO., LTD.Inventors: Daiki KANEKO, Takakuni MATSUDA, Yusuke HOSHIKA
-
Publication number: 20210361646Abstract: Disclosed are a method for producing an aripiprazole suspension, wherein the aripiprazole has a mean particle size of 1 to 10?m, the method comprising the steps of: (a) combining bulk aripiprazole and a vehicle to form a primary suspension; (b) subjecting the primary suspension to first pulverization using e.g., a high shear pulverizing machine, a dispersion machine that applies shear force to a material to be processed, a colloid mill, an ultrasonic dispersion machine, or a high-pressure jet type emulsifying dispersion machine to form a secondary suspension; and (c) subjecting the secondary suspension to second pulverization using e.g., a high-pressure jet type emulsifying dispersion machine to form a sterile final suspension; and a method for producing a freeze-dried formulation from the aripiprazole suspension.Type: ApplicationFiled: August 3, 2021Publication date: November 25, 2021Inventors: Shogo Hiraoka, Takakuni Matsuda, Junichi Hatanaka
-
Publication number: 20210338663Abstract: A controlled release sterile freeze-dried aripiprazole formulation is provided which is formed of aripiprazole of a desired mean particle size and a vehicle therefor, which upon constitution with water and intramuscular injection releases aripiprazole over a period of at least about one week and up to about eight weeks. A method for preparing the controlled release freeze-dried aripiprazole formulation, and a method for treating schizophrenia employing the above formulation are also provided.Type: ApplicationFiled: July 16, 2021Publication date: November 4, 2021Inventors: Janusz W. KOSTANSKI, Takakuni MATSUDA, Manoj NERURKAR, Vijay H. NARINGREKAR
-
Patent number: 11097007Abstract: An object of the present invention is to provide a storage-stable injectable preparation comprising a composition comprising a poorly soluble drug as an active ingredient and a dispersion medium. Another object of the present invention is to provide a compact, lightweight prefilled syringe by filling a syringe with the injectable preparation. The present invention provides an injectable preparation comprising a composition comprising a poorly soluble drug, a dispersion medium, and a specific suspending agent, the composition having a viscosity of 40 pascal-seconds or more in at least one point in the shear rate range of 0.01 to 0.02 s?1 and having a viscosity of 0.2 pascal-seconds or less in at least one point in the shear rate range of 900 to 1,000 s?1, as measured.Type: GrantFiled: December 1, 2020Date of Patent: August 24, 2021Assignee: OTSUKA PHARMACEUTICAL CO., LTD.Inventors: Daiki Kaneko, Takakuni Matsuda, Yusuke Hoshika
-
Publication number: 20210085794Abstract: An object of the present invention is to provide a storage-stable injectable preparation comprising a composition comprising a poorly soluble drug as an active ingredient and a dispersion medium. Another object of the present invention is to provide a compact, lightweight prefilled syringe by filling a syringe with the injectable preparation. The present invention provides an injectable preparation comprising a composition comprising a poorly soluble drug, a dispersion medium, and a specific suspending agent, the composition having a viscosity of 40 pascal-seconds or more in at least one point in the shear rate range of 0.01 to 0.02 s?1 and having a viscosity of 0.2 pascal-seconds or less in at least one point in the shear rate range of 900 to 1,000 s?1, as measured.Type: ApplicationFiled: December 1, 2020Publication date: March 25, 2021Applicant: OTSUKA PHARMACEUTICAL CO., LTD.Inventors: Daiki KANEKO, Takakuni MATSUDA, Yusuke HOSHIKA
-
Publication number: 20200246333Abstract: Disclosed are a method for producing an aripiprazole suspension, wherein the aripiprazole has a mean particle size of 1 to 10 ?m, the method comprising the steps of: (a) combining bulk aripiprazole and a vehicle to form a primary suspension; (b) subjecting the primary suspension to first pulverization using e.g., a high shear pulverizing machine, a dispersion machine that applies shear force to a material to be processed, a colloid mill, an ultrasonic dispersion machine, or a high-pressure jet type emulsifying dispersion machine to form a secondary suspension; and (c) subjecting the secondary suspension to second pulverization using e.g., a high-pressure jet type emulsifying dispersion machine to form a sterile final suspension; and a method for producing a freeze-dried formulation from the aripiprazole suspension.Type: ApplicationFiled: December 6, 2019Publication date: August 6, 2020Applicant: Otsuka Pharmaceutical Co., Ltd.Inventors: Shogo Hiraoka, Takakuni Matsuda, Junichi Hatanaka
-
Publication number: 20200179517Abstract: An object of the present invention is to provide a storage-stable injectable preparation comprising a composition comprising a poorly soluble drug as an active ingredient and a dispersion medium. Another object of the present invention is to provide a compact, lightweight prefilled syringe by filling a syringe with the injectable preparation. The present invention provides an injectable preparation comprising a composition comprising a poorly soluble drug, a dispersion medium, and a specific suspending agent, the composition having a viscosity of 40 pascal-seconds or more in at least one point in the shear rate range of 0.01 to 0.02 s?1 and having a viscosity of 0.2 pascal-seconds or less in at least one point in the shear rate range of 900 to 1,000 s?1, as measured.Type: ApplicationFiled: February 7, 2020Publication date: June 11, 2020Applicant: OTSUKA PHARMACEUTICAL CO., LTD.Inventors: Daiki KANEKO, Takakuni MATSUDA, Yusuke HOSHIKA
-
Publication number: 20200061057Abstract: A controlled release sterile freeze-dried aripiprazole formulation is provided which is formed of aripiprazole of a desired mean particle size and a vehicle therefor, which upon constitution with water and intramuscular injection releases aripiprazole over a period of at least about one week and up to about eight weeks. A method for preparing the controlled release freeze-dried aripiprazole formulation, and a method for treating schizophrenia employing the above formulation are also provided.Type: ApplicationFiled: October 30, 2019Publication date: February 27, 2020Inventors: Janusz W. KOSTANSKI, Takakuni MATSUDA, Manoj NERURKAR, Vijay H. NARINGREKAR
-
Patent number: 10517951Abstract: An object of the present invention is to provide a storage-stable injectable preparation comprising a composition comprising a poorly soluble drug as an active ingredient and a dispersion medium. Another object of the present invention is to provide a compact, lightweight prefilled syringe by filling a syringe with the injectable preparation. The present invention provides an injectable preparation comprising a composition comprising a poorly soluble drug, a dispersion medium, and a specific suspending agent, the composition having a viscosity of 40 pascal-seconds or more in at least one point in the shear rate range of 0.01 to 0.02 s?1 and having a viscosity of 0.2 pascal-seconds or less in at least one point in the shear rate range of 900 to 1,000 s?1, as measured.Type: GrantFiled: October 10, 2018Date of Patent: December 31, 2019Assignee: OTSUKA PHARMACEUTICAL CO., LTD.Inventors: Daiki Kaneko, Takakuni Matsuda, Yusuke Hoshika
-
Publication number: 20190336607Abstract: An object of the present invention is to provide a storage-stable injectable preparation comprising a composition comprising a poorly soluble drug as an active ingredient and a dispersion medium. Another object of the present invention is to provide a compact, lightweight prefilled syringe by filling a syringe with the injectable preparation comprising a composition comprising a poorly soluble drug, a dispersion medium, and a specific suspending agent, the composition having a viscosity of 40 pascal-seconds or more in at least one point in the shear rate range of 0.01 to 0.02 s?1 and having a viscosity of 0.2 pascal-seconds or less in at least one point in the shear rate range of 900 to 1,000 s?1, as measured.Type: ApplicationFiled: July 17, 2019Publication date: November 7, 2019Applicant: OTSUKA PHARMACEUTICAL CO., LTD.Inventors: Daiki KANEKO, Takakuni MATSUDA, Yusuke HOSHIKA
-
Publication number: 20190099494Abstract: An object of the present invention is to provide a storage-stable injectable preparation comprising a composition comprising a poorly soluble drug as an active ingredient and a dispersion medium. Another object of the present invention is to provide a compact, lightweight prefilled syringe by filling a syringe with the injectable preparation. The present invention provides an injectable preparation comprising a composition comprising a poorly soluble drug, a dispersion medium, and a specific suspending agent, the composition having a viscosity of 40 pascal-seconds or more in at least one point in the shear rate range of 0.01 to 0.02 s?1 and having a viscosity of 0.2 pascal-seconds or less in at least one point in the shear rate range of 900 to 1,000 s?1, as measured.Type: ApplicationFiled: October 10, 2018Publication date: April 4, 2019Applicant: OTSUKA PHARMACEUTICAL CO., LTD.Inventors: Daiki KANEKO, Takakuni MATSUDA, Yusuke HOSHIKA
-
Publication number: 20180185358Abstract: Disclosed are a method for producing an aripiprazole suspension, wherein the aripiprazole has a mean particle size of 1 to 10 ?m, the method comprising the steps of: (a) combining bulk aripiprazole and a vehicle to form a primary suspension; (b) subjecting the primary suspension to first pulverization using e.g., a high shear pulverizing machine, a dispersion machine that applies shear force to a material to be processed, a colloid mill, an ultrasonic dispersion machine, or a high-pressure jet type emulsifying dispersion machine to form a secondary suspension; and (c) subjecting the secondary suspension to second pulverization using e.g., a high-pressure jet type emulsifying dispersion machine to form a sterile final suspension; and a method for producing a freeze-dried formulation from the aripiprazole suspension.Type: ApplicationFiled: December 27, 2017Publication date: July 5, 2018Inventors: Shogo Hiraoka, Takakuni Matsuda, Junichi Hatanaka
-
Publication number: 20180055941Abstract: An object of the present invention is to provide a storage-stable injectable preparation comprising a composition comprising a poorly soluble drug as an active ingredient and a dispersion medium. Another object of the present invention is to provide a compact, lightweight prefilled syringe by filling a syringe with the injectable preparation. The present invention provides an injectable preparation comprising a composition comprising a poorly soluble drug, a dispersion medium, and a specific suspending agent, the composition having a viscosity of 40 pascal-seconds or more in at least one point in the shear rate range of 0.01 to 0.02 s?1 and having a viscosity of 0.2 pascal-seconds or less in at least one point in the shear rate range of 900 to 1,000 s?1, as measured.Type: ApplicationFiled: September 11, 2017Publication date: March 1, 2018Applicant: OTSUKA PHARMACEUTICAL CO., LTD.Inventors: Daiki KANEKO, Takakuni MATSUDA, Yusuke HOSHIKA
-
Publication number: 20170348308Abstract: A controlled release sterile freeze-dried aripiprazole formulation is provided which is formed of aripiprazole of a desired mean particle size and a vehicle therefor, which upon constitution with water and intramuscular injection releases aripiprazole over a period of at least about one week and up to about eight weeks. A method for preparing the controlled release freeze-dried aripiprazole formulation, and a method for treating schizophrenia employing the above formulation are also provided.Type: ApplicationFiled: August 18, 2017Publication date: December 7, 2017Inventors: Janusz W. KOSTANSKI, Takakuni MATSUDA, Manoj NERURKAR, Vijay H. NARINGREKAR
-
Patent number: 9809609Abstract: The present invention provides a benzoazepine compound represented by following general formula (1): or a salt thereof, wherein R represents a hydrogen atom, a hydroxy group optionally protected with a protecting group, etc., R1 represents a hydrogen atom or hydroxy-protecting group, and X represents an oxygen atom or a sulfur atom. The benzoazepine compound of the present invention and salts thereof have high solubility in water, and can be suitably used for injections.Type: GrantFiled: May 1, 2012Date of Patent: November 7, 2017Assignee: OTSUKA PHARMACEUTICAL CO., LTD.Inventors: Makoto Komatsu, Fumitaka Goto, Yasuhiro Menjo, Keigo Yamada, Takakuni Matsuda, Yusuke Kato
-
Patent number: 9763935Abstract: A controlled release sterile freeze-dried aripiprazole formulation is provided which is formed of aripiprazole of a desired mean particle size and a vehicle thereof, which upon constitution with water and intramuscular injection releases aripiprazole over a period of at least about one week and up to about eight weeks. A method for preparing the controlled release freeze-dried aripiprazole formulation, and a method for treating schizophrenia employing the above formulation are also provided.Type: GrantFiled: October 6, 2014Date of Patent: September 19, 2017Assignee: Otsuka Pharmaceutical Co., Ltd.Inventors: Janusz W. Kostanski, Takakuni Matsuda, Manoj Nerurkar, Vijay H. Naringrekar
-
Injectable depot formulation comprising optically active tolvaptan and process of producing the same
Patent number: 9597283Abstract: This invention provides an injectable formulation to be administered intramuscularly or subcutaneously that is used for the prevention or treatment of polycystic kidney disease, and that can maintain a therapeutically effective blood concentration of tolvaptan for a long period of time; and a process for producing the same. More specifically, this invention relates to an injectable depot formulation comprising (1) a particle containing optically active tolvaptan as an active ingredient and (2) a pharmaceutically acceptable carrier for injection, and a process for producing the same.Type: GrantFiled: December 27, 2013Date of Patent: March 21, 2017Assignee: OTSUKA PHARMACEUTICAL CO., LTD.Inventors: Daiki Kaneko, Takakuni Matsuda, Kenichi Miyata, Kai Suzuki, Hiroyuki Fujiki, Shizuo Kinoshita, Koji Ohmoto, Miki Aihara